DSpace Repositorium (Manakin basiert)

Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study

Zur Kurzanzeige

dc.contributor.author Castiglione, Juan Ignacio
dc.contributor.author Rivero, Alberto Daniel
dc.contributor.author Barroso, Fabio Adrián
dc.contributor.author Brand, Patricio
dc.contributor.author Lautre, Andrea Rosana
dc.contributor.author Kohler, Alejandro Alfredo
dc.date.accessioned 2022-08-31T17:31:37Z
dc.date.available 2022-08-31T17:31:37Z
dc.date.issued 2022-08-31
dc.identifier.citation Castiglione JI, Rivero AD, Barroso F, Brand P, Lautre AR, Kohler AA. Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study. J Clin Neuromuscul Dis. 2022 Sep 1;24(1):18-25. doi: 10.1097/CND.0000000000000420. es_ES
dc.identifier.issn 1537-1611
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/663
dc.identifier.uri https://doi.org/10.1097/cnd.0000000000000420
dc.description.abstract Objetive: Rituximab (RTX) is a therapeutic option, for patients with myasthenia gravis (MG) not responding to conventional immunosuppressive treatment. In this cohort, we evaluated long-term efficacy of RTX in the treatment of refractory generalized MG. Methods: A retrospective study was performed in adult patients with refractory generalized MG and at least 24 months of follow-up, between January/2015 and October/2021. The Myasthenia Gravis Status and Treatment Intensity Score was used to assess outcomes, and CD19/CD20+ B-cell counts were monitored. Results: Sixteen patients with MG (8 antiacetylcholine receptor+ and 8 muscle-specific antikinase+; mean age 45.5 ± 16.2 years) treated with low-dose RTX protocols were included. CD19/CD20 levels remained undetectable 12 months after induction, and no new relapses were observed during follow-up. Conclusions: Low-dose RTX infusions were sufficient to achieve undetectable CD19/20 cell counts and sustained clinical remission. In low and middle-income countries, the impact of low-dose RTX therapy represents a paradigm shift in decision-making for long-term treatment. es_ES
dc.language.iso eng es_ES
dc.publisher Wolters Kluwer Health es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Neoplasm Recurrence, Local / drug therapy es_ES
dc.subject Retrospective Studies es_ES
dc.subject Myasthenia Gravis / drug therapy es_ES
dc.subject Miastenia Gravis /tratamiento farmacológico es_ES
dc.subject Estudios retrospectivos es_ES
dc.subject Recurrencia Local de Neoplasia / tratamiento farmacológico es_ES
dc.title Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Castiglione, Juan Ignacio. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Rivero, Alberto Daniel. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Barroso, Fabio Adrián. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Brand, Patricio. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Lautre, Andrea Rosana. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Kohler, Alejandro Alfredo. Fleni. Departamento de Neurología; Argentina.
dc.relation.ispartofVOLUME 24
dc.relation.ispartofNUMBER 1
dc.relation.ispartofPAGINATION 18-25
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Hagerstown, MD
dc.relation.ispartofTITLE J Clin Neuromuscul Dis
dc.relation.ispartofISSN 1537-1611
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Dateien zu dieser Ressource

Das Dokument erscheint in:

Zur Kurzanzeige

info:eu-repo/semantics/openAccess Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: info:eu-repo/semantics/openAccess

DSpace Suche


Stöbern

Mein Benutzerkonto

Statistik